Overview

Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
An evaluation of the safety and efficacy of the calcineurin inhibitor, pimecrolimus cream 1%, in adult patients with perioral dermatitis. This study is not enrolling patients in the United States.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Pimecrolimus
Tacrolimus